Revolution- Study drug RMC-5127 for advanced KRAS G12V solid tumors (RMC-5127-001)

Who Can Participate in the Study?

Age Group
Adults

Study Details

Full Title
[RMC-5127-001] Phase 1/1b, Multicenter, Open-Label, Study of RMC-5127 in Patients with Advanced KRAS G12V-Mutant Solid Tumors
Principal Investigator
Headshot of John Strickler
Professor of Medicine
Protocol Number
IRB: PRO00119569
NCT: NCT07349537
Phase
Phase I
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL
Participate